MONOPAR THERAPEUTICS INC (MNPR) Stock Analyst Ratings
USA - NASDAQ:MNPR - US61023L2079 - Common Stock
85.67 USD
+1.52 (+1.8%)
ChartMill assigns a Buy % Consensus number of 84% to MNPR. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 99.28. This target is 15.89% above the current price.
MNPR was analyzed by 17 analysts. The buy percentage consensus is at 84. So analysts seem to be very confident about MNPR.
In the previous month the buy percentage consensus was at a similar level.
MNPR was analyzed by 17 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-10-13 | Barclays | Initiate | Overweight |
| 2025-10-06 | Raymond James | Maintains | Strong Buy -> Strong Buy |
| 2025-10-02 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2025-09-29 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-09-25 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-09-25 | BTIG | Maintains | Buy -> Buy |
| 2025-09-25 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2025-09-23 | Lake Street | Initiate | Buy |
| 2025-09-16 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-09-15 | BTIG | Reiterate | Buy -> Buy |
| 2025-09-09 | BTIG | Initiate | Buy |
| 2025-09-03 | Oppenheimer | Initiate | Outperform |
| 2025-09-03 | Raymond James | Initiate | Strong Buy |
| 2025-08-27 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2025-08-13 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-07-07 | Cantor Fitzgerald | Initiate | Overweight |
| 2025-06-23 | Chardan Capital | Initiate | Buy |
| 2025-04-02 | Jones Trading | Downgrade | Buy -> Hold |
| 2025-04-01 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-01-22 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-01-10 | Piper Sandler | Initiate | Overweight |
| 2024-11-11 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-10-11 | Rodman & Renshaw | Initiate | Buy |
| 2024-08-14 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-05-10 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-04-11 | JonesTrading | Upgrade | Hold -> Buy |
| 2023-06-01 | HC Wainwright & Co. | Reiterate | Buy |
| 2023-05-15 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-03-29 | Maxim Group | Downgrade | Buy -> Hold |
| 2023-03-28 | EF Hutton | Maintains | Buy |
MONOPAR THERAPEUTICS INC / MNPR FAQ
What is the average price target for MONOPAR THERAPEUTICS INC (MNPR) stock?
17 analysts have analysed MNPR and the average price target is 99.28 USD. This implies a price increase of 15.89% is expected in the next year compared to the current price of 85.67.
Can you provide the consensus rating for MONOPAR THERAPEUTICS INC stock?
The consensus rating for MONOPAR THERAPEUTICS INC (MNPR) is 83.5294 / 100 . This indicates that analysts generally have a positive outlook on the stock.
How many analysts cover MONOPAR THERAPEUTICS INC (MNPR) stock?
The number of analysts covering MONOPAR THERAPEUTICS INC (MNPR) is 17.